LDLR and atherosclerosis: The purpose of the current study was to investigate the influence of proteasome inhibition with bortezomib at a low dose of 50 μg/kg BW, a treatment previously shown to attenuate early atherogenesis [7], on pre-existing, advanced atherosclerosis in LDLR−/− mice.